bpc-157 before and after Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats Frontiers | Stable Gastric Pentadecapeptide

Using peptides without a proper diagnosis risks treating the wrong problem while a serious underlying condition goes unaddressed

Current research suggests BPC-157 does not appear to be harmful to the kidneys and may demonstrate protective properties in certain preclinical studies

Additionally, the absorption rate of subcutaneous injection is slower compared to intramuscular and intravenous

However, BPC-157 has never completed human clinical trials, so its safety profile in humans is unknown

**Not labeling the vial:** Two weeks from now you will not remember when you reconstituted it

In the United States, the Food and Drug Administration (FDA) oversees peptides, classifying them as drugs or biologics based on their composition and intended use